Victoza Approved to Treat Type 2 Diabetes
Victoza Approved to Treat Type 2 Diabetes
Victoza Is a Once-Daily Injection for Adults With Type 2 Diabetes
The FDA notes that in animal studies, Victoza caused tumors of the thyroid gland in rats and mice. Some of those tumors were cancers, which were more likely in rats that got doses of Victoza that were eight times higher than what people would receive.
It's not known if Victoza could cause thyroid tumors or a very rare type of thyroid cancer called medullary thyroid cancer in people. For that reason, the FDA says Victoza should not be used as the first treatment for diabetes until more studies are done.
Victoza should not be used in people who are already at risk for medullary thyroid cancer, such as those who have medullary thyroidcancer in the family, or those with a rare genetic condition called multiple endocrine neoplasia syndrome type 2.
Victoza has a risk evaluation and mitigation strategy to help patients and health-care providers understand the drug's risks and to ensure that the drug's benefits outweigh the risk of acute pancreatitis and the potential risk of medullary thyroid cancer.
Victoza is made by the drug company Novo Nordisk. The launch price of the 1.2-milligram dose will be $8.03 a day.
New Diabetes Drug Victoza Approved
Victoza Is a Once-Daily Injection for Adults With Type 2 Diabetes
FDA's Victoza Decision continued...
The FDA notes that in animal studies, Victoza caused tumors of the thyroid gland in rats and mice. Some of those tumors were cancers, which were more likely in rats that got doses of Victoza that were eight times higher than what people would receive.
It's not known if Victoza could cause thyroid tumors or a very rare type of thyroid cancer called medullary thyroid cancer in people. For that reason, the FDA says Victoza should not be used as the first treatment for diabetes until more studies are done.
Victoza should not be used in people who are already at risk for medullary thyroid cancer, such as those who have medullary thyroidcancer in the family, or those with a rare genetic condition called multiple endocrine neoplasia syndrome type 2.
Victoza has a risk evaluation and mitigation strategy to help patients and health-care providers understand the drug's risks and to ensure that the drug's benefits outweigh the risk of acute pancreatitis and the potential risk of medullary thyroid cancer.
Victoza is made by the drug company Novo Nordisk. The launch price of the 1.2-milligram dose will be $8.03 a day.
Source...